NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Alkermes 

88 Sidney Street

Cambridge  Massachusetts  02139-4136  U.S.A.
Phone: 617-494-0171 Fax: 617-494-9263


SEARCH JOBS


Alkermes, Inc., a biotechnology company committed to developing innovative medicines to improve patients’ lives, manufactures RISPERDAL® CONSTA® for schizophrenia and developed and manufactures VIVITROL® for alcohol dependence. Alkermes’ robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research and manufacturing facilities in Massachusetts and Ohio.

Collaborative Agreements
To maximize the potential for products to make a difference in patients' lives, Alkermes has development and marketing agreements with some of the world's leading pharmaceutical companies:

• Amylin Pharmaceuticals, Inc.
• Cephalon, Inc.
• Janssen-Cilag, a wholly owned division of Johnson & Johnson
• Cilag GmbH International

Amylin Pharmaceuticals, Inc.

In collaboration with Amylin Pharmaceuticals, Inc., we have developed exenatide once weekly, a Medisorb® formulation of BYETTA® (exenatide) for the treatment of type 2 diabetes. This long-acting release formulation has the potential to provide important therapeutic benefits in a once-weekly dosing regimen.

• Alkermes is responsible for developing potential long-acting formulations of exenatide.
• Amylin is responsible for conducting clinical trials, securing regulatory approvals, manufacturing exenatide once weekly for commercial sale, and for the sales and marketing of any products resulting from the collaboration.
• Alkermes will receive royalty payments on net product sales.
• Amylin has entered a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including certain rights to exenatide once weekly.

Cephalon, Inc.

Alkermes is collaborating with Cephalon, Inc. on the development and commercialization of VIVITROL® (naltrexone for extended-release injectable suspension) in the U.S.

• Alkermes is responsible for manufacturing and clinical development of VIVITROL.
• Cephalon has primary responsibility for the marketing and sale of VIVITROL in the U.S., and Alkermes augments this sales effort.

Janssen-Cilag

Alkermes is collaborating with Janssen-Cilag (Janssen), a division of Johnson & Johnson, to market RISPERDAL® CONSTA® [(risperidone) long-acting injection], a long-acting injection of the oral medicine RISPERDAL® (risperidone) for the treatment of schizophrenia. RISPERDAL CONSTA uses Alkermes’ Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks.

• Janssen markets RISPERDAL CONSTA in over 60 countries worldwide, including the U.S. and major European markets.
• Alkermes is responsible for manufacturing RISPERDAL CONSTA.

Cilag GmbH International

We have an agreement with Cilag GmbH International, a subsidiary of Johnson & Johnson, to commercialize VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence in Russia and other countries in the Commonwealth of Independent States (CIS).

• Janssen-Cilag, an affiliate company of Cilag GmbH International, is responsible for securing all necessary regulatory approvals and will commercialize VIVITROL in Russia and other countries in the Commonwealth of Independent States (CIS).
• Alkermes is responsible for manufacturing VIVITROL and will receive manufacturing revenues and royalty revenues based on product sales.


 Key Statistics


Email:
Ownership:
Web Site: Alkermes
Employees:
Symbol: ALKS
 



Industry
Biotechnology


Collaborations

Amylin Pharmaceuticals, Inc.  In May 2000, Amylin signed an agreement with Alkermes to develop, manufacture and commercialize an injectable, long-acting formulation of exenatide, called Exenatide LAR.





 Company News
Alkermes (ALKS) Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence 11/17/2009 8:41:10 AM    More...
Alkermes (ALKS) Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence 11/16/2009 9:33:40 AM    More...
Alkermes (ALKS) to Seek FDA Approval of Anti-Addiction Drug 11/16/2009 7:45:56 AM    More...
Alkermes (ALKS)' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference 11/11/2009 10:06:30 AM    More...
Alkermes (ALKS) Reports Second Quarter Fiscal 2010 Financial Results 11/6/2009 9:53:41 AM    More...
Alkermes (ALKS)’ Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference 11/5/2009 9:53:16 AM    More...
Alkermes (ALKS) to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2010 10/30/2009 9:15:55 AM    More...
Alkermes (ALKS) Announces Initiation of Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation 10/27/2009 9:02:12 AM    More...
Alkermes (ALKS) Announces Positive Results From Two Clinical Trials of ALKS 33 10/13/2009 9:15:15 AM    More...
Alkermes (ALKS) Announces Amylin Pharmaceuticals, Inc. (AMLN) and Eli Lilly and Company (LLY) Will Present More than 20 Studies for Exenatide at EASD 2009 9/24/2009 9:34:51 AM    More...
12345678910...